FiercePharma4d
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
STAT3d
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
The Washington Post4d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects ...
London South East3d
PureTech receives $29m royalty from Karuna schizophrenia treatment
PureTech advanced its KarXT treatment through its own founded entity Karuna Therapeutics, which was acquired by Bristol Myers Squibb in March. Along with a royalty agreement with Royalty Pharma ...
ENDPOINTS NEWS4d
End­points 11 win­ner Sea­port Ther­a­peu­tics: The Karuna team is back with an­oth­er big bet in neu­ro­science
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...